Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01729819 |
|
Recruitment Status :
Completed
First Posted : November 20, 2012
Results First Posted : August 14, 2018
Last Update Posted : September 12, 2018
|
Sponsor:
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Ferring Pharmaceuticals
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of nocturnal voids during 3 months of treatment
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Overactive Bladder | Drug: Tolterodine tartrate extended release capsules Drug: Desmopressin orally disintegrating tablets Drug: Placebo orally disintegrating tablets | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 106 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women |
| Study Start Date : | January 2013 |
| Actual Primary Completion Date : | November 2014 |
| Actual Study Completion Date : | November 2014 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Urine and Urination
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Combination
Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
|
Drug: Tolterodine tartrate extended release capsules Drug: Desmopressin orally disintegrating tablets |
|
Active Comparator: Tolterodine
Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets
|
Drug: Tolterodine tartrate extended release capsules Drug: Placebo orally disintegrating tablets |
Primary Outcome Measures :
- Change in Mean Number of Nocturnal Voids From Baseline [ Time Frame: Baseline to 3 months of treatment ]A nocturnal void was defined as a void occurring at least 5 minutes after going to bed, but before getting up the next morning. The mean estimate was the average over 3 consecutive 24-hour periods prior to the respective visit as captured in the voiding and sleep diary.
Secondary Outcome Measures :
- Change in Mean Time to First Nocturnal Void From Baseline [ Time Frame: Baseline to 3 months of treatment ]The time to first nocturnal void was defined as the time from going to bed with the intention of sleeping until first nocturnal void or until waking in the morning in the case there is no nocturnal void. The time to first void was calculated as the average over three consecutive 24-hour periods prior to the respective visits.
- Change in Mean Nocturnal Urine Volume From Baseline [ Time Frame: Baseline to 3 months of treatment ]The mean nocturnal urine volume was derived from the three-day urine volume diary. The nocturnal volume was defined as the sum of the volumes for all nocturnal voids including the volume of the first morning void within 30 min of waking up in the morning.
- Responder Status [ Time Frame: Baseline to 3 months of treatment ]Responder status was defined as ≥33% decrease in the mean number of nocturnal void and at least one night with no voids out of the 3-day diary period.
- Onset of Effect as Seen in Change in Mean Number of Nocturnal Voids From Baseline for Each Visit During Three Months of Treatment [ Time Frame: Baseline to 3 months of treatment ]A nocturnal void was defined as a void occurring at least 5 minutes after going to bed, but before getting up the next morning. The mean estimate was the average over 3 consecutive 24-hour periods prior to the respective visit as captured in the voiding and sleep diary.
- Change in the Impact on Sleep as Measured by the Sleep Rating Scales From Baseline [ Time Frame: Baseline to 3 months of treatment ]An electronic diary was used in the trial to document the impact on sleep quality (sleep rating scales). The sleep rating scales included three questions that ranged from 0 (poor) to 10 (good). The average of each question for each visit was summarised and the change from baseline was analysed longitudinally during the three months of treatment.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written informed consent prior to performance of any trial-related activity
- Female sex, at least 18 years of age (at the time of written consent)
- Nocturia and overactive bladder symptoms present for ≥6 months prior to trial entry (patient-reported)
- At least 2 nocturnal voids each night as documented in 2 diary periods during the screening. A mean of at least 8 daytime voids per day over 3 days with a minimum of at least 6 daytime voids each day as documented in 2 diary periods during the screening. At least 1 urgency episode each 24 hours as documented in 2 diary periods during the screening. Each diary period consists of 3 consecutive days, with at least 14 days between each period.
Exclusion Criteria:
- Evidence of severe voiding dysfunction defined as:
More than 10 nocturnal voids per 24 hours as documented on any of the days in both diary periods during screening.
More than 20 daytime voids per 24 hours as documented on any of the days in both diary periods during screening.
- Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract infections, interstitial cystitis, bladder related pain, or stone in the bladder and urethra causing symptoms
- Current or a history within 5 years of lower urologic malignancies (e.g., bladder cancer), lower urinary tract surgery, previous pelvic irradiation, or severe neurological disease affecting bladder function or muscle strength (e.g., multiple sclerosis, Parkinson's disease, spinal cord injury, spina bifida)
- Symptoms of severe stress urinary incontinence in the opinion of the investigator
- Urinary retention or a post void residual volume in excess of 150 mL as confirmed by bladder ultrasound performed after suspicion of urinary retention
- Habitual or psychogenic polydipsia (fluid intake resulting in a urine production exceeding 40 mL/kg/24 hours) or a mean volume voided per void of 350 mL or more during one or more 24-hour periods as assessed by the screening diaries
- Central or nephrogenic diabetes insipidus
- Syndrome of inappropriate antidiuretic hormone (SIADH)
- Gastric retention
- Myasthenia gravis
- Uncontrolled narrow-angle glaucoma
- Suspicion or evidence of cardiac failure
- Uncontrolled and clinically relevant (in the judgement of the investigator) hypertension or diabetes mellitus
- History and/or current treatment of obstructive sleep apnoea
- Hyponatraemia:Serum sodium level must not be below 135 mmol/L
- Evidence of potential renal impairment:Serum creatinine must be within normal laboratory reference intervals AND estimated glomerular filtration rate must be more than or equal to 50 mL/min
- Hepatic and/or biliary diseases: Aspartate aminotransferase and/or alanine aminotransferase levels must not be more than twice the upper limit of normal range. Total bilirubin level must not be more than 1.5 mg/dL
- Pregnancy, breastfeeding, or a plan to become pregnant during the period of the trial. Women of reproductive age must have documentation of a reliable method of contraception. All pre- and perimenopausal women have to perform pregnancy tests. Amenorrhea of more than 12 months duration based on the reported date of the last menstrual period is sufficient documentation of post-menopausal status and does not require a pregnancy test
- Known alcohol or substance abuse; work or lifestyle that may interfere with regular night-time sleep e.g., shift workers; or any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, illiteracy or language barrier which, in the judgement of the investigator, would impair participation in the trial
- Known or suspected hypersensitivity to any active ingredient or excipients in the investigational medicinal products used in the trial
- Previous participation in any desmopressin trial within the last 5 years
- Use of any prohibited therapy, as defined in the protocol
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01729819
Locations
Show 24 study locations
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
| Study Director: | Clinical Development Support | Ferring Pharmaceuticals |
| Responsible Party: | Ferring Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01729819 |
| Other Study ID Numbers: |
000085 |
| First Posted: | November 20, 2012 Key Record Dates |
| Results First Posted: | August 14, 2018 |
| Last Update Posted: | September 12, 2018 |
| Last Verified: | August 2018 |
Additional relevant MeSH terms:
|
Urinary Bladder, Overactive Nocturia Urinary Bladder Diseases Urologic Diseases Lower Urinary Tract Symptoms Urological Manifestations Deamino Arginine Vasopressin Tolterodine Tartrate Muscarinic Antagonists Cholinergic Antagonists |
Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents Hemostatics Coagulants Antidiuretic Agents Natriuretic Agents |